IDXX
IDEXX Laboratories Inc
IDEXX Laboratories Inc historical holders
total: 6
Jensen Investment Management IDEXX Laboratories Inc transactions over time
- Total transactions:
- 8
- New positions:
- 1
- Added:
- 3
- Reduced:
- 4
- Held since:
- 2024 Q2
- Held for:
- 8 quarters
- Latest activity:
- 2026 Q1
Eric H. Schoenstein has been an institutional investor in IDEXX Laboratories Inc (IDXX) since 2024 Q2. According to 2026 Q1 report, Eric H. Schoenstein holds 3,570 shares with a market value of roughly $2.01M representing 0.04% of their equity portfolio. The fund/company first acquired IDXX in 2024 Q2, initially purchasing 5,120 shares. Since the initial investment, Jensen Investment Management has made 7 more transactions in this position.
Does Eric H. Schoenstein still hold IDXX?
Yes, Eric H. Schoenstein continues to hold IDEXX Laboratories Inc (IDXX). According to their 2026 Q1 report, they maintain a position of 3,570 shares valued at approximately $2.01M, representing 0.04% of their equity portfolio.
When did Eric H. Schoenstein first invest in IDXX?
Eric H. Schoenstein first invested in IDEXX Laboratories Inc (IDXX) in 2024 Q2 at the reported quarter-end price of $487.20 per share, acquiring 5,120 shares in their initial purchase.
What is Eric H. Schoenstein's average cost basis for IDXX?
Based on historical transaction data, Eric H. Schoenstein's estimated cost basis for IDEXX Laboratories Inc (IDXX) is approximately $495.56 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $495.56
- Weighted AVG sell price:
- $619.40
IDXX transactions history by Jensen Investment Management
8 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
0.04%
|
3,570
|
$561.89
|
$2,005,947
|
-0.03% (-1)
|
-0%
|
|
2025 Q4
|
0.04%
|
3,571
|
$676.53
|
$2,415,889
|
-19.39% (-859)
|
-0.01%
|
|
2025 Q3
|
0.04%
|
4,430
|
$638.89
|
$2,830,283
|
-57.44% (-5,980)
|
-0.04%
|
|
2025 Q2
|
0.07%
|
10,410
|
$536.34
|
$5,583,299
|
+27.11% (+2,220)
|
+0.01%
|
|
2025 Q1
|
0.04%
|
8,190
|
$419.95
|
$3,439,391
|
-9.20% (-830)
|
-0%
|
|
2024 Q4
|
0.03%
|
9,020
|
$413.44
|
$3,729,229
|
+11.50% (+930)
|
+0%
|
|
2024 Q3
|
0.03%
|
8,090
|
$505.22
|
$4,087,230
|
+58.01% (+2,970)
|
+0.01%
|
|
2024 Q2
|
0.02%
|
5,120
|
$487.20
|
$2,494,464
|
new
|
+0.02%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.